MCRB (Seres Therapeutics) Change In Receivables : $4.66 Mil (TTM As of Mar. 2025)

View and export this data going back to 2015. Start your Free Trial

What is Seres Therapeutics Change In Receivables?

Seres Therapeutics's change in receivables for the quarter that ended in Mar. 2025 was $-0.69 Mil. It means Seres Therapeutics's Accounts Receivable increased by $0.69 Mil from Dec. 2024 to Mar. 2025 .

Seres Therapeutics's change in receivables for the fiscal year that ended in Dec. 2024 was $6.61 Mil. It means Seres Therapeutics's Accounts Receivable declined by $6.61 Mil from Dec. 2023 to Dec. 2024 .

Seres Therapeutics's Accounts Receivable for the quarter that ended in Mar. 2025 was $2.76 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Seres Therapeutics's liquidation value for the three months ended in Mar. 2025 was $-52.80 Mil.

Seres Therapeutics Change In Receivables Historical Data

The historical data trend for Seres Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Seres Therapeutics Change In Receivables Chart

Seres Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

-7.60

9.39

-8.67

6.61

Seres Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Receivables	Get a 7-Day Free Trial															1.26	-11.18	18.60	-2.07	-0.69

Seres Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.66 Mil.

Seres Therapeutics (NAS:MCRB) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Seres Therapeutics's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	2.761	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Seres Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Seres Therapeutics's liquidation value for the quarter that ended in Mar. 2025 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	58.849	-	113.717	+	0.75 * 2.761	+	0.5 * 0
=	-52.80

Seres Therapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Seres Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Seres Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Seres Therapeutics Inc (NAS:MCRB) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

1S90:Germany

Address

101 Cambridgepark Drive, Cambridge, MA, USA, 02140

Website

https://www.serestherapeutics.com

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

Executives

Matthew R. Henn	officer: Chief Scientific Officer	C/O SERES THERAPEUTICS, INC., 200 SIDNEY STREET, CAMBRIDGE MA 02139
Eric D. Shaff	officer: CFO and EVP	C/O SERES HEALTH, INC., 161 FIRST STREET, CAMBRIDGE MA 02472
Teresa L. Young	officer: See Remarks	C/O SERES THERAPEUTICS, INC., SUITE 1750, HOUSTON TX 77098
Thomas Desrosier	officer: See Remarks	65 HAYDEN AVENUE, LEXINGTON MA 02421
Moltke Lisa Von	officer: See Remarks	C/O SERESTHERAPEUTICS, INC., 200 SIDNEY STREET, CAMBRIDGE MA 02139
David S. Ege	officer: See Remarks	C/O SERES THERAPEUTICS, INC., 200 SIDNEY STREET, CAMBRIDGE MA 02139
David Arkowitz	officer: Chief Financial Officer	C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Paula Cloghessy	officer: See Remarks	C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Claire Fraser	director	C/O BECTON, DICKINSON AND COMPANY, FRANKLIN LAKES NJ 07465
Flagship Pioneering Fund Vii General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Pioneering Fund Vii, L.p.	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Nutritional Health Ltp Fund, L.p.	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Ventures Fund Iv, L.p.	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Ventures Fund Iv General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship Ventures Fund Iv-rx, L.p.	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142